The role of IL-23/IL-17 axis in human kidney allograft rejection

Haouami, Youssra; Dhaouadi, Tarak; Sfar, Imen; Bacha, Mohamed Mongi; Gargah, Tahar; Bardi, R.; Abderrahim, E.; Goucha, R.; Abdallah, T. Ben; Gorgi, Yousr

doi:10.1002/jlb.5ab0318-148r

Cited by 13 publications

(6 citation statements)

References 27 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Th17 cell subsets were associated with autoimmune diseases, tumor immunity, and transplant rejection 33 . Th17 cell subsets and IL‐17A mRNA expression significantly increased after acute rejection in kidney transplant recipients 34,35 . With the decrease in Th17 cell subsets and IL‐17 expression, chronic rejection, renal tissue injury and serum Cr level also improved 36 .…”

Section: Discussionmentioning

confidence: 98%

“…33 Th17 cell subsets and IL-17A mRNA expression significantly increased after acute rejection in kidney transplant recipients. 34,35 With the decrease in Th17 cell subsets and IL-17 expression, chronic rejection, renal tissue injury and serum Cr level also improved. 36 In the research of RA, IGU could reduce Th17 cell subsets and the production of cytokines such as IL-17A, and inhibit the expression of Th17-related transcription factors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Iguratimod reduces panel reactive antibody in high mismatched renal transplant recipients: One single‐center experience

Feng

Huang

Chen

et al. 2022

Clinical Transplantation

View full text Add to dashboard Cite

Objective: To evaluate the clinical efficacy and safety of iguratimod (IGU) for reducing panel reactive antibody (PRA) in high-mismatched renal transplant recipients. Methods:Eligible recipients positive for PRAs who received or did not receive IGU treatment were enrolled. We retrospectively reviewed, collected, and analyzed statistically the clinical data of the recipients.Results: A total of 80 recipients were included for further analysis. After IGU was administered for 9 months, no significant difference was found in the change rates of donor specific antibodies between two groups. Meanwhile, the reduction in the PRAs in the IGU group was greater than that in the non-IGU group in anti-human leukocyte antigen (HLA) class I and class II, anti-HLA class I, anti-HLA class II, anti-HLA A, and anti-HLA DR antibodies. However, no differences were found in the anti-HLA B, anti-HLA Cw, anti-HLA DP, and anti-HLA DQ antibodies between the two groups.No serious adverse events were reported, and the incidence of adverse events was comparable between the two groups. Conclusion:PRA levels in high-mismatched renal transplant recipients were significantly reduced after the administration of IGU. The high safety of IGU was also determined.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Iguratimod reduces panel reactive antibody in high mismatched renal transplant recipients: One single‐center experience

Feng

Huang

Chen

et al. 2022

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…In mice with no Th1 response, Th17 cells mediate rapid allograft rejection ( 76 ). Th17 associated molecules such as IL-17A and IL-23 are increased in RT patients with acute rejection ( 77 ). Increased Th17 relative to Foxp3 cells in renal allograft biopsies indicates a poorer outcome ( 78 ) as does increased Th17 cells in blood ( 79 ).…”

Section: The Rejection Response To An Allograft Is Heterogeneousmentioning

confidence: 99%

CD4+CD25+ T regulatory cells in renal transplantation

et al. 2022

View full text Add to dashboard Cite

The immune response to an allograft activates lymphocytes with the capacity to cause rejection. Activation of CD4+CD25+Foxp3+T regulatory cells (Treg) can down-regulate allograft rejection and can induce immune tolerance to the allograft. Treg represent <10% of peripheral CD4+T cells and do not markedly increase in tolerant hosts. CD4+CD25+Foxp3+T cells include both resting and activated Treg that can be distinguished by several markers, many of which are also expressed by effector T cells. More detailed characterization of Treg to identify increased activated antigen-specific Treg may allow reduction of non-specific immunosuppression. Natural thymus derived resting Treg (tTreg) are CD4+CD25+Foxp3+T cells and only partially inhibit alloantigen presenting cell activation of effector cells. Cytokines produced by activated effector cells activate these tTreg to more potent alloantigen-activated Treg that may promote a state of operational tolerance. Activated Treg can be distinguished by several molecules they are induced to express, or whose expression they have suppressed. These include CD45RA/RO, cytokine receptors, chemokine receptors that alter pathways of migration and transcription factors, cytokines and suppression mediating molecules. As the total Treg population does not increase in operational tolerance, it is the activated Treg which may be the most informative to monitor. Here we review the methods used to monitor peripheral Treg, the effect of immunosuppressive regimens on Treg, and correlations with clinical outcomes such as graft survival and rejection. Experimental therapies involving ex vivo Treg expansion and administration in renal transplantation are not reviewed.

show abstract

“…Studies on solid organ transplantation including bone marrow transplantation have highlighted the importance of polymorphisms of the IL-17F and IL-17A genes in the pathogenesis of allograft rejection (16). The association between IL-17A (17) and IL-17F gene polymorphisms with acute rejection (16) and the use of IL-17 serum levels as the primary marker of acute rejection (18,19) have been reported in kidney transplantation. IL-17F gene SNP 7489A/G is linked with graft failure (20).…”

Section: Zununi Vahed S Et Almentioning

confidence: 99%

IL-17 gene polymorphism (rs763780) in kidney recipients with post-transplant diabetes

et al. 2022

View full text Add to dashboard Cite

Introduction: New-onset diabetes mellitus after transplantation (NODAT) is a common complication of organ transplantation, leading to allograft dysfunction. Genetic alterations of inflammatory cytokines have been reported to be associated with glucose homeostasis and diabetes. Objectives: This study evaluated the rs763780 polymorphism of IL-17F gene in transplant recipients with and without NODAT. Patients and Methods: The present retrospective study was conducted on ninety-one patients who have had a kidney transplant for at least three months. Patients were divided into two subgroups; recipients with NODAT (n=32) and kidney recipients without NODAT (n=59). After DNA extraction from patients’ blood samples, amplification and evaluation of specific polymorphism of the gene were performed using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Clinical and demographic data of patients were collected. Results: The NODAT was detected in 81.3% (n=26) of TT genotype carriers, 12.5% of TC genotype carriers and 6.3% of CC genotype carriers. No statistically significant differences between the studied groups in the frequency of C and T alleles and the distribution of the abovementioned genotypes were detected (P≥0.721). In the NODAT group, graft rejection and age of patients were higher significantly (P≤0.017). Conclusion: No significant correlation between the incidence of diabetes and rs763780 polymorphism of IL-17F gene was observed.

show abstract

The role of IL-23/IL-17 axis in human kidney allograft rejection

Cited by 13 publications

References 27 publications

Iguratimod reduces panel reactive antibody in high mismatched renal transplant recipients: One single‐center experience

Iguratimod reduces panel reactive antibody in high mismatched renal transplant recipients: One single‐center experience

CD4+CD25+ T regulatory cells in renal transplantation

IL-17 gene polymorphism (rs763780) in kidney recipients with post-transplant diabetes

Contact Info

Product

Resources

About